First Trust Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

First Trust Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.44M	Sell	85,506 -2,999	-3%	-$292K	0.01%	1240
2025 Q4	$9.47M	Buy	88,505 +7,602	+9%	+$806K	0.01%	1122
2025 Q3	$8.17M	Buy	80,903 +7,189	+10%	+$667K	0.01%	1158
2025 Q2	$4.66M	Sell	73,714 -16,065	-18%	-$984K	﹤0.01%	1383
2025 Q1	$4.76M	Sell	89,779 -28,558	-24%	-$1.58M	﹤0.01%	1337
2024 Q4	$6.62M	Buy	118,337 +47,575	+67%	+$2.63M	0.01%	1216
2024 Q3	$3.71M	Sell	70,762 -20,248	-22%	-$970K	﹤0.01%	1478
2024 Q2	$3.74M	Buy	+91,010	New	+$3.63M	﹤0.01%	1423
2023 Q4	–	Sell	-75,315	Closed	-$1.73M	–	2424
2023 Q3	$1.73M	Buy	75,315 +31,150	+71%	+$698K	﹤0.01%	1744
2023 Q2	$728K	Buy	+44,165	New	+$797K	﹤0.01%	2054

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

First Trust Advisors's RYTM Position: Q1 2026 in Review

First Trust Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 3.4% in Q1 2026, selling an estimated $292K and leaving 85,506 shares worth $7.44M. The position accounts for 0.01% of the portfolio, ranked #1240.

First Trust Advisors first reported a position in RYTM in Q2 2023 and has held it in 10 quarters since. The position peaked at $9.47M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

First Trust Advisors held 85,506 shares of Rhythm Pharmaceuticals worth $7.44M as of Q1 2026.
First Trust Advisors sold 2,999 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $292K.
Rhythm Pharmaceuticals made up 0.01% of First Trust Advisors's portfolio in Q1 2026, its #1240 holding.
First Trust Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2023 and has held it in 10 quarters since.
First Trust Advisors's Rhythm Pharmaceuticals position peaked at $9.47M in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.